Cure of Pulmonary Rhizomucor Pusillus Infection in a Patient with Hairy-Cell Leukemia: Role of Liposomal Amphotericin B and GM-CSF

References

• Kontoyiannis D. P., Wessel V. C., Bodey G. P., Rolston K. V. Zygomycosis in the 1990s in a tertiary-care center. Clinical Infectious Disease 2000; 30: 851–856
   PubMed Web of Science ®Google Scholar
• St-Germain G., Robert A., Ishak M., Tremblay C., Claveau S. Infection due to Rhizomucor pusillus: report of 4 cases in patients with leukemia and review. Clinical Infectious Disease 1993; 16: 640–645
   PubMed Web of Science ®Google Scholar
• Parfrey N. A. Improved diagnosis and prognosis of mucormycosis. A clinicopathologic study of 33 cases. Medicine 1986; 65: 113–123
   PubMed Web of Science ®Google Scholar
• Rinaldi M. G. Zygomycosis. Infectious Disease Clinic of North America 1989; 3: 9–41
   Google Scholar
• Meyer R. D., Rosen P., Armstrong D. Phycomycosis complicating leukemia and lymphoma. Annals of Internal Medicine 1972; 77: 871–879
   PubMed Web of Science ®Google Scholar
• Pagano L., Ricci P., Tonso A., Nosari A., Cudillo L., Montillo M., Cenacchi A., Pacilli L., Fabbiano F., Del-Favero A. Mucormycosis in patients with haemato-logical malignancies: a retrospective clinical study of 37 cases. British Journal of Haematology 1997; 99: 331–336
   PubMed Web of Science ®Google Scholar
• Janoff A. S., Perkins W. R. Amphotericin B lipid complex: a molecular rationale for the attenuation of amphotericin B related toxicities. Journal of Liposome Research 1993; 3: 451–471
   Google Scholar
• Walsh T. J., Hiemenz J. W., Seibel N. L., Perfect J. R., Howith G., Lee L., Silber J. L., DiNubile M. J., Reboli A., Bow E., Lister J., Anaissie E. J. Amphotericin B lipid complex for invasive fungal infections: Analysis of safety and efficacy in 556 cases. Clinical Infectious Disease 1998; 26: 1383–1396
   PubMed Web of Science ®Google Scholar
• Walsh T. J., Finberg R. W., Arndt C., Hiemens J., Schwartz C., Bodensteiner D., Pappas P., Seibel N., Greenberg R. N., Dummer S., Schust M., Holcenberg J. S. Liposomal amphotericin B for empirical therapy of patients with persistent fever and neutropenia. New England Journal of Medicine 1999; 340: 764–771
   PubMed Web of Science ®Google Scholar
• Wingard J. R., White M. H., Anaissie E., Raffalli J., Goodman J., Arrieta A. A randomized, double-blind comparative trial evaluating the safety of liposomal amphotericin B versus amphotericin B lipid complex in the empirical treatment of febrile neutropenia. Clinical Infectious Disease 2000; 31: 1155–1163
   PubMed Web of Science ®Google Scholar
• Leenders A. C., Daenen S., Jansen R. L., Hop W. C., Lowenberg B., Wjerman D. W., Cornelissen J., Herbrecht R., Vanderlelie H., Hoogsteden H. C., Verbrugh H. A., deMarie S. Liposomal amphotericin B compared with amphotericin B deoxycholate in the treatment of documented and suspected neutropenia-associated invasive fungal infections. British Journal of Haematology 1998; 103: 205–212
   PubMed Web of Science ®Google Scholar
• White M. H., Anaissie E. J., Kusne S., Wingard J. R., Hiemenz J. W., Cantor A., Gurwith M., DuMond C., Mamelok R. D., Bowden R. A. Amphotericin B colloidal dispersion vs. amphotericin B as therapy for invasive aspergillosis. Clinical Infectious Disease 1997; 24: 635–642
   PubMed Web of Science ®Google Scholar
• Ellis M., Spence D., DePauw B., Meunin F., Marinus A., Collette L., Sylvester R., Meis J., Boogaerk M., Selleslag D., Krcmeny V., Von Sinner W., MacDonald P., Doyen C., Vandercam B. EORTC 19923. Multicenter trial comparing doses of liposomal amphotericin B for the treatment of invasive aspergillosis. Clinical Infectious Disease 1998; 27: 1406–1472
   PubMed Web of Science ®Google Scholar
• Rodriguez-Adrian L. J., Grazziutti M. L., Rex J. H., Anaissie E. J. The potential role of cytokine therapy for fungal infections in patients with cancer: Is recovery from neutropenia all that is needed?. Clinical Infectious Disease 1998; 26: 1270–1278
   PubMed Web of Science ®Google Scholar
• Bodey G. P., Anaissie E., Gutterman J., Vanhorn-Raj S. Role of granulocyte macrophage colony-stimulating factor as adjuvant therapy for fungal infections in patients with cancer. Clinical Infectious Disease 1993; 17: 705–707
   PubMed Web of Science ®Google Scholar
• Nemunaitis J., Shannon-Dorcy K., Appelbaum F. R., Meyer S. J., Owens A., Day R., Ando D., O'Neill C., Buckner D., Singer E. Longterm follow-up of patients with invasive fungal disease who received adjunctive therapy with recombinant human macrophage colony-stimulating factor. Blood 1993; 82: 1422–1427
   PubMed Web of Science ®Google Scholar
• Saven A., Burian C., Adusumalli J., Koziol J. A. Filgrastim for cladribine-induced neutropenic fever in patients with hairy cell leukemia. Blood 1999; 93: 2471–2477
   PubMed Web of Science ®Google Scholar
• Christopoulos C., Fortis A., Nikzas D., Anevlavis E. The place of myeloid growth factors in the treatment of hairy-cell leukaemia. Clinical Laboratory Haematology 1997; 19: 149–150
   PubMedGoogle Scholar
• Osterholz J., Wohlleber M., Kahnt C., Schumacher K. The use of interferon-alpha and granulocyte colony-stimulating factor in hairy cell leukaemia with aplastic marrow. European Journal of Haematology 1995; 55: 140–142
   PubMed Web of Science ®Google Scholar
• Couban S., Wilson W. E. Use of 2-chlorodeoxyade-nosine, granulocyte-colony-stimulating factor, and erythropoietin in a Jehovah's Witness with hairy cell leukemia. American Journal of Hematology 1995; 49: 255–256
   PubMed Web of Science ®Google Scholar
• Lorber C., Willfort A., Ohler L., Jager U., Schweninger I., Lechner K., Geissler K. Granulocyte colony-stimulating factor (rh G-CSF) as an adjunct to interferon alpha therapy of neutropenic patients with hairy cell leukemia. Annals of Hematology 1993; 67: 13–16
   PubMed Web of Science ®Google Scholar
• Glaspy J. A., Souza L., Scates S., Narachi M., Blatt L., Ambersley J., Golde D. W. Treatment of hairy cell leukemia with granulocyte colony-stimulating factor and recombinant consensus interferon or recombinant interferon-alpha-2b. Journal of Immunotherapy 1992; 11: 198–208
   PubMed Web of Science ®Google Scholar
• Glaspy J. A., Baldwin G. C., Robertson P. A., Souza L., Vincent M., Ambersley J., Golde D. W. Therapy for neutropenia in hairy cell leukemia with recombinant human granulocyte colony-stimulating factor. Annals of Internal Medicine 1988; 109: 789–795
   PubMed Web of Science ®Google Scholar
• Lindemann A., Herrmann F., Mertelsmann R., Gamm H., Rumpelt H. J. Splenic hematopoiesis following GM-CSF therapy in a patient with hairy cell leukemia. Leukemia 1990; 4: 606–607
   PubMed Web of Science ®Google Scholar
• Peterslund N. A., Boesen A.M. GM-CSF treatment of a patient with hairy-cell leukaemia. A potentially effective treatment?. European Journal of Haematology 1994; 53: 249–250
   PubMed Web of Science ®Google Scholar
• Juliusson G., Lenkei R., Tjonnfjord G., Heldal D., Liliemark J. Neutropenic fever following cladribine therapy for symptomatic hairy-cell leukemia: predictive factors and effects of granulocyte-macrophage colony-stimulating factor. Annals of Oncology 1995; 6: 371–375
   PubMed Web of Science ®Google Scholar
• Grigg A. P., Roberts A. W., Raunow H., Houghton S., Layton J. E., Boyd A. W., McGrath K. M., Maher D. Optimizing dose and scheduling of filgrastim (granulocyte colony-stimulating factor) for mobilization and collection of peripheral blood progenitor cells in normal volunteers. Blood 1995; 86: 4437–4445
   PubMed Web of Science ®Google Scholar
• Roberts A. W., Foote S., Alexander W. S., Scott C., Robb L., Metcalf D. Genetic influences determining progenitor cell mobilization and leukocytosis induced by granulocyte colony-stimulating factor. Blood 1997; 89: 2736–2744
   PubMed Web of Science ®Google Scholar
• Winter J. N., Lazarus H. M., Rademaker A., Villa M., Mangan C., Tallman M., Jahnke L., Gordon L., Newman S., Byrd K., Cooper B. W., Horvath N., Crum E., Stadtmauer E. A., Conklin E., Bauman A., Martin J., Goolsby C., Gerson S. L., Bender J., O'Gorman M. Phase I/II study of combined granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor administration for the mobilization of hematopoetic progenitor cells. Journal of Clinical Oncology 1996; 14: 277–286
   PubMed Web of Science ®Google Scholar
• Metcalf D. Hematopoietic regulators: redundancy or subtlety?. Blood 1993; 82: 3515–3523
   PubMed Web of Science ®Google Scholar